Zhihong Y, Chen W, Qianqian Z, Lidan S, Qiang Z, Jing H, et al
Manufacturing Capacity and Supply Chain Investment: In a bid to avoid previous shortages of injectable GLP-1s, Eli Lilly has amassed a $1.5 billion pre-launch inventory of its oral weight loss drug orforglipron ahead of FDA decision expected in April 2026 [4]
[Source: EurekAlert / EASD 2025] Researchers noted that it remains unclear whether these improvements stem from the reduction in food noise itself or from the weight loss that accompanied treatment, but the direction of the findings is consistent across measures
This is why CJC-1295 no DAC is also known as tetrasubstituted GRF (1-29), modified GRF (1-29) or simply mod GRF (1-29) [10]
Your care, organized in one place Track medications, labs, and treatment plans easily through your secure patient dashboard
XW and RY prepared the original manuscript